Therapeutic potential of implantable replacement hearts.
In patients hospitalized with decompensated life-threatening heart failure, the impact of newer pharmacologic therapies and mechanical circulatory support has not yet been realized, except for those who are bridged to cardiac transplantation. For long-term support of transplant-ineligible patients who have severe biventricular failure that is refractory to optimized pharmacologic therapy, replacement of the natural heart with a totally implantable mechanical replacement heart, capable of producing blood flow of up to 8 to 10 L/min, may become the most well tolerated and effective treatment. This article summarizes the current status of the first generation implantable replacement heart (AbioCor trade mark, ABIOMED. Inc., Danvers, MA). With regard to optimizing the further enhancement of treatment options for end-stage heart failure and other life-threatening illnesses, the pharmacodynamics-like principle of therapeutic efficiency should play a role in the development of both drugs and devices. In keeping with that principle, we recommend that adjusting a product's design input requirements to maximize the therapeutic effect per exposure and;to separate the cumulative therapeutic effects of the product from the cumulative adverse effects (of the product, and of the comorbid disease processes in the patients treated) should be part of the good product development process for any therapeutic product.
Lederman
David M
DM
ABIOMED Inc., Danvers, Massachusetts 01923, USA.
Kung
Robert T V
RT
McNair
Douglas S
DS
D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000601:surgery*; D006354:Heart, Artificial / Q000639:trends*; D006801:Humans